Skip to main content
. Author manuscript; available in PMC: 2014 May 21.
Published in final edited form as: Hum Pathol. 2012 Apr 26;43(12):2129–2137. doi: 10.1016/j.humpath.2012.01.009

Table 6.

Adjusted Cox model for immunoexpression of biomarkers as prognosticators of outcome in papillary RCC a

Biomarkers b,c Overall mortality
Cancer-specific mortality
Tumor progression
HR P HR P HR P
PTEN 1.00 (0.99–1.01) .73 1.00 (0.99–1.01) .97 1.00 (0.99–1.01) .38
phos-AKT 0.28 (0.05–1.68) .16 0.01 (0.01–6.61) .13 0.22 (0.02–2.55) .22
phos-S6 1.00 (0.99–1.02) .73 1.01 (0.99–1.03) .38 1.01 (0.99–1.03) .45
phos-4EBP1 1.00 (0.99–1.01) .84 1.00 (0.99–1.01) .43 1.00 (0.99–1.01) .92
p27 1.01 (1.00–1.02) .19 1.01 (0.99–1.03) .35 1.01 (1.00–1.03) .05
HIF-1α 1.01 (0.99–1.04) .37 1.02 (0.98–1.05) .44 1.01 (0.97–1.04) .68
a

Values provided correspond to hazard ratios (HRs) with 95% CIs in parenthesis. Each marker was entered separately.

b

Adjusted for T stage, Fuhrman grade, and tumor size.

c

HRs for c-MYC were excluded due to extremely low values.